Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 1
2008 1
2010 2
2012 3
2013 3
2014 7
2015 10
2016 9
2017 8
2018 13
2019 17
2020 14
2021 25
2022 23
2023 37
2024 33

Text availability

Article attribute

Article type

Publication date

Search Results

179 results

Results by year

Filters applied: . Clear all
Page 1
Current and future status of JAK inhibitors.
McLornan DP, Pope JE, Gotlib J, Harrison CN. McLornan DP, et al. Lancet. 2021 Aug 28;398(10302):803-816. doi: 10.1016/S0140-6736(21)00438-4. Lancet. 2021. PMID: 34454676 Review.
SIMPLIFY-1: A Phase III Randomized Trial of Momelotinib Versus Ruxolitinib in Janus Kinase Inhibitor-Naïve Patients With Myelofibrosis.
Mesa RA, Kiladjian JJ, Catalano JV, Devos T, Egyed M, Hellmann A, McLornan D, Shimoda K, Winton EF, Deng W, Dubowy RL, Maltzman JD, Cervantes F, Gotlib J. Mesa RA, et al. Among authors: mclornan d. J Clin Oncol. 2017 Dec 1;35(34):3844-3850. doi: 10.1200/JCO.2017.73.4418. Epub 2017 Sep 20. J Clin Oncol. 2017. PMID: 28930494 Free PMC article. Clinical Trial.
Preface.
McLornan D. McLornan D. Best Pract Res Clin Haematol. 2022 Jun;35(2):101383. doi: 10.1016/j.beha.2022.101383. Epub 2022 Sep 9. Best Pract Res Clin Haematol. 2022. PMID: 36333069 No abstract available.
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study.
Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Ocroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Verstovsek S, et al. Among authors: mclornan d. Lancet. 2023 Jan 28;401(10373):269-280. doi: 10.1016/S0140-6736(22)02036-0. Lancet. 2023. PMID: 36709073 Clinical Trial.
A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline.
McMullin MF, Harrison CN, Ali S, Cargo C, Chen F, Ewing J, Garg M, Godfrey A, S SK, McLornan DP, Nangalia J, Sekhar M, Wadelin F, Mead AJ; BSH Committee. McMullin MF, et al. Among authors: mclornan dp. Br J Haematol. 2019 Jan;184(2):176-191. doi: 10.1111/bjh.15648. Epub 2018 Nov 27. Br J Haematol. 2019. PMID: 30478826 Free article. Review. No abstract available.
Guideline for the investigation and management of eosinophilia.
Butt NM, Lambert J, Ali S, Beer PA, Cross NC, Duncombe A, Ewing J, Harrison CN, Knapper S, McLornan D, Mead AJ, Radia D, Bain BJ; British Committee for Standards in Haematology. Butt NM, et al. Among authors: mclornan d. Br J Haematol. 2017 Feb;176(4):553-572. doi: 10.1111/bjh.14488. Epub 2017 Jan 23. Br J Haematol. 2017. PMID: 28112388 Free article. No abstract available.
A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline.
McMullin MFF, Mead AJ, Ali S, Cargo C, Chen F, Ewing J, Garg M, Godfrey A, Knapper S, McLornan DP, Nangalia J, Sekhar M, Wadelin F, Harrison CN; British Society for Haematology Guideline. McMullin MFF, et al. Among authors: mclornan dp. Br J Haematol. 2019 Jan;184(2):161-175. doi: 10.1111/bjh.15647. Epub 2018 Nov 13. Br J Haematol. 2019. PMID: 30426472 Free PMC article. Review. No abstract available.
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group.
Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, Gupta V, Hamad N, Harrison C, Hernandez-Boluda JC, Koschmieder S, Jain T, Mascarenhas J, Mesa R, Popat UR, Passamonti F, Polverelli N, Rambaldi A, Robin M, Salit RB, Schroeder T, Scott BL, Tamari R, Tefferi A, Vannucchi AM, McLornan DP, Barosi G. Kröger N, et al. Among authors: mclornan dp. Lancet Haematol. 2024 Jan;11(1):e62-e74. doi: 10.1016/S2352-3026(23)00305-8. Epub 2023 Dec 4. Lancet Haematol. 2024. PMID: 38061384 Review.
Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT.
Polverelli N, Hernández-Boluda JC, Czerw T, Barbui T, D'Adda M, Deeg HJ, Ditschkowski M, Harrison C, Kröger NM, Mesa R, Passamonti F, Palandri F, Pemmaraju N, Popat U, Rondelli D, Vannucchi AM, Verstovsek S, Robin M, Colecchia A, Grazioli L, Damiani E, Russo D, Brady J, Patch D, Blamek S, Damaj GL, Hayden P, McLornan DP, Yakoub-Agha I. Polverelli N, et al. Among authors: mclornan dp. Lancet Haematol. 2023 Jan;10(1):e59-e70. doi: 10.1016/S2352-3026(22)00330-1. Epub 2022 Dec 6. Lancet Haematol. 2023. PMID: 36493799 Review.
Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey.
Passweg JR, Baldomero H, Ciceri F, Corbacioglu S, de la Cámara R, Dolstra H, Glass B, Greco R, McLornan DP, Neven B, de Latour RP, Perić Z, Ruggeri A, Snowden JA, Sureda A. Passweg JR, et al. Among authors: mclornan dp. Bone Marrow Transplant. 2023 Jun;58(6):647-658. doi: 10.1038/s41409-023-01943-3. Epub 2023 Mar 6. Bone Marrow Transplant. 2023. PMID: 36879108 Free PMC article.
179 results